For how we live.
In 62 adults scanned under psilocybin during rest, meditation, music, and film, brain networks reorganized differently by setting — and more reorganization tracked with more positive experiences.
The agency compressed review of three psychedelic therapies from a year to weeks. A first approval decision is plausible by early 2027.
A review pooling 23 studies found risk concentrated among people with bipolar I disorder, family history, or unsupervised use. About 4% later transitioned to bipolar disorder.
By the study's end, 70% had scores low enough to be considered near-resolution. There was no placebo arm — every participant knew what they'd received.
EPISODE randomized 144 people with treatment-resistant depression across four arms. High-dose psilocybin missed its main outcome, even as secondary measures showed symptom benefit.
No medication has proven effective for cocaine use disorder. A single psilocybin dose, paired with therapy, produced more abstinent days and a longer time to relapse than an active placebo.
In 35 patients with recurrent major depression, psilocybin beat an active placebo through day 42. On self-reported measures the effect lingered further, but the trial's primary endpoint showed no difference at 365 days.
TSND-201 improved PTSD severity, disability, and depression scores over placebo in 65 participants — delivered as an oral dose with monitoring but no formal psychotherapy alongside it.
Twenty-four healthy volunteers received all three drugs in a crossover trial. At 30 mg, 2C-B matched MDMA's intensity and produced psilocybin-like states, without psilocybin's anxiety.
The open-label pilot tested a specific worry in psychedelic research — that borderline personality disorder blunts response to psilocybin for depression. In this small sample, it didn't.
A survey of 243 people reporting persistent difficulty after a psychedelic trip found that how they responded in the moment, avoiding versus accepting, predicted whether trauma symptoms followed.
Most psychedelic depression trials require patients to come off antidepressants first. This one deliberately didn't — and found intranasal 5-MeO-DMT tolerable and encouraging in patients who stayed on their SSRI.
Up to eight sessions of psilocybin, layered onto a small randomized comparison against an active placebo, produced a 73% response rate by the end of treatment. The trial was designed to test safety first.
Six months out, 40.5% of smokers given one high dose of psilocybin plus therapy stayed abstinent, versus 10% on the nicotine patch plus the same therapy. The trial ran 82 people.
Pooling 31 studies of 556 patients, cortical 5-HT2A binding was lower in unmedicated depression than in controls. The post-mortem studies mostly found nothing, and the tracers used shape the result.